In addition, IFN-administered patients often develop arthritis as an adverse drug reaction [34–36], which indicates that the increased levels of type I IFN, triggered by a viral infection or other immunological stimuli, may be involved in the pathogenesis of pre-clinical or early RA. Here, IFNA1 is linked to rheumatoid arthritis.